Medication Risk Communication in Rheumatology: Where Are We and Where Do We Go from Here?
This paper reviews findings from recent research examining issues related to the risk communication process within the context of rheumatologic conditions. Five specific questions are addressed. First, to what extent do patients with rheumatic disorders exhibit adequate knowledge relevant to disease and medication risks and risk management? Second, what sources do patients use when attempting to find information about disease and medication risks and risk management? Third, what types of information about disease and medication risks and risk management do rheumatologists provide during routine office visits. Fourth, what governmental regulations attempt to increase consumer access to information about medication risks and risk management? Finally, what other educational resources are available to facilitate patient-provider communication concerning disease and medication risks and risk management? The findings reported identify gaps in patient knowledge concerning medication risks and risk management, highlight areas for improvement, and identify resources that may enhance medication risk communication.
Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599-7573, USA. s_blalock@unc.edu.
Susan J
SJ
Blalock
D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003142:Communication; D006801:Humans; D010817:Physician-Patient Relations; D012216:Rheumatic Diseases / Q000188:drug therapy*; D012219:Rheumatology
D018501:Antirheumatic Agents
Arthritis; Medication guides; Medications; Patient-provider communication; Risk communication